BioSpace News Archive

Immunocore Holdings plc is presenting two posters at the 2023 American Society for Clinical Oncology meeting.

Zevra Therapeutics, Inc. will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 - 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters.

Apexigen, Inc. announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin, in patients with advanced soft tissue sarcoma.

Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced positive interim clinical data from the ongoing Phase 1 study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy.

Allogene Therapeutics, Inc. presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory large B-cell lymphoma at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

Cyteir Therapeutics, Inc. presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled “Phase 1 Results of CYT-0851, a Monocarboxylate Transporter Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors” at the 2023 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

Exai Bio announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.

Merck, known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery and after surgery, for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer.

GRAIL, LLC announced results from a retrospective analysis of the interventional PATHFINDER study to assess whether diagnostic evaluations of individuals who received a cancer signal detected result with the Galleri® multi-cancer early detection test were appropriately directed by the test’s cancer signal origin predictions.